<DOC>
	<DOC>NCT02826044</DOC>
	<brief_summary>SP2086 is a novel inhibitor of Dipeptide base peptidase 4, allows an insulin-independent approach to improve type 2 diabetes hyperglycemia. In this single-dose and multiple-dose study the investigators evaluated the safety, tolerability and Pharmacokinetics profiles of SP2086 in healthy volunteers.</brief_summary>
	<brief_title>The Pharmacokinetics Study of Single and Multiple Dose of SP2086 in Healthy Volunteers</brief_title>
	<detailed_description />
	<criteria>BMI(a measure of a person's weight in relation to height)is between 19 and 26 kg/m2,and the weight is equal or less than 100kg. without the history of cardiovascular diseases,liver diseases,kidney diseases,gastrointestinal tract diseases,mental nerve diseases and drug allergy. Be willing to accept physical contraception. Sign the informed consents voluntarily and ensure to completed the study. Known allergy to SP2086 or any of the excipients of the formulation of SP2086; ever occured myocardial infarction,acute coronary syndrome, transient ischemic attack. the B hepatitis surface antigen or hepatitis C antibody or syphilis antibody or HIV antibody was positive. had participated three or more clinical trial in one year or had participated one time clinical medicine in one month of screening. have the history of blood donation in 3 months of screening or received the blood transfusion in 1 months of screening. have the history of tobacco,alcohol or drug abuse. History of or current clinically significant medical illness as determined by the Investigator.</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>45 Years</maximum_age>
	<verification_date>April 2016</verification_date>
</DOC>